References: Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study
Soliqua 100/33 Dosage and Administration 2.1 Important Dosage Information SOLIQUA 100/33 is a combination of insulin glargine and lixisenatide
GLP-1(7-37) , Dulaglutide 8 , 22 , 36 .113 G4(IgG4) (Fc) -(----) 3-- G4(IgG4) (Fc) , 90.105 (Dulaglutide) GLP-1RA, 1 .33,78,104,114 2 1 GLP-1RA .115 GLP-1(7-37) , 8 , 34 , 26 .31 , PEG
Its now spreading into cardiology, hepatology, nephrology and sleep medicine The Old Narrative: A Weight-Loss Race For a long time, this was a two-horse race: Semaglutide ~1315% weight loss Tirzepatide ~20%+ weight loss Even head-to-head: 20.2% vs 13.7% mean weight loss Nearly 2x more patients hitting 25% weight loss That made the conclusion easy: Tirzepatide wins But that conclusion is already outdated
Most listeners of this podcast arent just chasing a smaller number on the scale